Zamir Halpern

Zamir Halpern

Auto-generated profile, based on publicly available information

Zamir Halpern

Department of Gastroenterology, Tel Aviv Sourasky Medical Center

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 October 2016 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
RARan Afik
Ran Afik
EZEhud Zigmond
Ehud Zigmond
MVMilena Vugman
Milena Vugman
MKMordehay Klepfish
Mordehay Klepfish
ESElee Shimshoni
Elee Shimshoni
CVChen Varol
Chen Varol
Tumor-associated macrophages (TAMs) promote tumor development, invasion, and dissemination by various mechanisms. In this study, using an orthotopic colorectal cancer (CRC) model, we found that monocyte-derived TAMs advance tumor development by the remodeling of its extracellular matrix (ECM) composition and structure. Unbiased transcriptomic and proteomic analyses of (a) TAM-abundant and -deficient tumor tissues and (b) sorted tumor-associated and -resident colonic macrophage subpopulations defined a distinct TAM-induced ECM molecular signature composed of an ensemble of matricellular proteins and remodeling enzymes they provide to the tumor microenvironment. Remarkably, many of these ECM proteins are specifically increased in human CRC versus healthy colon. Specifically, we demonstrate that although differentiating into TAMs, monocytes up-regulate matrix-remodeling programs associated with the synthesis and assembly of collagenous ECM, specifically collagen types I, VI, and XIV. This finding was further established by advanced imaging showing that TAMs instruct the deposition, cross-linking, and linearization of collagen fibers during tumor development, especially at areas of tumor invasiveness. Finally, we show that cancer-associated fibroblasts are significantly outnumbered by TAMs in this model and that their expression of collagen XIV and I is reduced by TAM deficiency. Here, we outline a novel TAM protumoral function associated with building of the collagenous ECM niche.

1 October 2018 in Journal of Clinical Gastroenterology
Verified
Journal Article
Closed access
NINaomi Fliss Isakov
Naomi Fliss Isakov
SZShira Zelber-Sagi
Shira Zelber-Sagi
MWMuriel Webb
Muriel Webb
ZHZamir Halpern
Zamir Halpern
RKRevital Kariv
Revital Kariv
Goals: The goal of this study is to test the association between lifetime smoking habits and colorectal polyps of different classifications. Background: Smoking is an established risk factor for several cancers, including colorectal cancer. However, the association between lifetime smoking habits including intensity, duration, and cessation, and premalignant colorectal polyps is yet to be established. Study: A case-control study among 828 consecutive subjects aged 40 to 70 years, undergoing screening or diagnostic colonoscopy. Exclusion criteria were: medically treated diabetes, colectomy, and belonging to colorectal cancer high risk group. Polyps were stratified according to histology (serrated or adenomatous polyp) and location. All participants underwent anthropometric measurements and a structured medical and lifestyle interview. Results: Current-smoking was more strongly associated with increased odds for distal rather than proximal polyps [odds ratio (OR), 4.00; 95% confidence interval (CI), 2.40-6.68 and OR, 2.52; 95% CI, 1.46-4.36, respectively], with serrated-polyps rather than adenomas (OR, 6.36; 95% CI, 2.77-14.57 and OR, 3.01; 1.90-4.74, respectively). All levels of smoking intensity (daily cigarettes) were associated with colorectal polyps. A dose-response association was seen between smoking duration and colorectal polyps. Smoking duration of ≥20 years was strongly associated with distal polyps (OR, 4.01; 95% CI, 1.62-9.84), independently of potential confounders, smoking intensity and years since smoking cessation. All associations were stronger for distal serrated polyps. Conclusions: Smoking duration is associated with colorectal plyps, independently of other potential confounders, smoking intensity, and cessation. The association is stronger with distal rather than proximal polyps, and with serrated polyps rather than adenomas.

7 May 2003 in Liver International
Verified
Journal Article
Closed access
PDF file
RKR. Kariv
R. Kariv
AEA. Enden
A. Enden
IZIsab Zvibel
Isab Zvibel
GRG. Rosner
G. Rosner
SBS. Brill
S. Brill
ROR. Oren
R. Oren

1 March 2002 in Hepatology
Verified
Journal Article
Open access
PDF file
TGTuvia Gilat
Tuvia Gilat
Alicia Isabel Leikin FrenkelAlicia Isabel Leikin Frenkel
Alicia Isabel Leikin Frenkel
IGIlana Goldiner
Ilana Goldiner
ZHZamir Halpern
Zamir Halpern
FKFred M. Konikoff
Fred M. Konikoff
Gallstones, mostly cholesterol stones, affect some 15% of the population. Oral bile salts dissolve human cholesterol gallstones, but with low efficacy, and surgery remains the main therapeutic option. Fatty acid bile acid conjugates (FABACs) were shown to prevent formation of cholesterol gallstones in experimental animals. The aim of this study was to test whether these compounds could dissolve preexisting cholesterol gallstones via oral administration. Inbred, gallstone-susceptible C57J/L mice were given a lithogenic diet for 2 months, and the presence of gallstones was ascertained. The mice were then switched to a regular diet while part of them were given in addition C20-FABAC, by gavage, at a dose of 0.5 or 3 mg per animal per day. All mice tested had cholesterol gallstones after 2 months on the lithogenic diet. In study I, after 2 months on the regular diet, 3 of 4 (75%) of the controls had gallstones, whereas none of the 6 FABAC-fed animals (3 mg/d) had stones (P = .033). In study II, evaluating 2 FABAC doses, after 2 months on the regular diet, 8 of 8 (100%) of the controls had gallstones, which were found in 2 of 7 (28%) and 1 of 8 (12%) of the mice supplemented with 0.5 mg/d (P = .007) or 3 mg/d (P = .001) FABAC, respectively. On a molar basis, the dose of 0.5 mg FABAC is equivalent to 14 mg/kg/d of a bile acid. In conclusion, FABACs given orally can dissolve preexisting cholesterol gallstones in mice. This was accomplished with a dose of FABAC equivalent to the dose of bile acids used in human gallstone dissolution.

1 May 2014 in Gastroenterology
Verified
Journal Article
Closed access
NGNathan Gluck
Nathan Gluck
SFSigal Fishman
Sigal Fishman
AMAlaa Melhem
Alaa Melhem
SGSharon Goldfarb
Sharon Goldfarb
ZHZamir Halpern
Zamir Halpern
ESErwin Santo
Erwin Santo

1 May 2015 in Gastrointestinal Endoscopy
Verified
Journal Article
Closed access
NGNathan Gluck
Nathan Gluck
AMAlaa Melhem
Alaa Melhem
ZHZamir Halpern
Zamir Halpern
KMKlaus Mergener
Klaus Mergener
SGSharon Goldfarb
Sharon Goldfarb
ESErwin Santo
Erwin Santo